United Therapeutics CorpNASDAQ:UTHR
- LAST PRICE352.4900
- TODAY'S CHANGE (%)0.0200 (0.0057%)
- Bid / Lots352.1000/ 4
- Ask / Lots353.0300/ 2
- Open / Previous Close352.3500 / 352.4700
- Day Range
- 52 Week Range
- Volume79,479
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | UTHR |
|---|---|---|
| 09:32 ET | 1950 | 350.925 |
| 09:39 ET | 364 | 354.08 |
| 09:41 ET | 1200 | 354.615 |
| 09:43 ET | 300 | 354.785 |
| 09:45 ET | 499 | 352.93 |
| 09:48 ET | 300 | 352.89 |
| 09:50 ET | 200 | 354.19 |
| 09:57 ET | 100 | 354 |
| 09:59 ET | 158 | 354.54 |
| 10:01 ET | 300 | 355.17 |
| 10:03 ET | 600 | 355.9 |
| 10:06 ET | 200 | 356.42 |
| 10:08 ET | 500 | 356.21 |
| 10:10 ET | 1730 | 356.23 |
| 10:12 ET | 100 | 356.345 |
| 10:14 ET | 1396 | 357.04 |
| 10:15 ET | 425 | 356.41 |
| 10:21 ET | 700 | 355.685 |
| 10:24 ET | 400 | 355.42 |
| 10:26 ET | 800 | 354.325 |
| 10:30 ET | 787 | 354.465 |
| 10:32 ET | 427 | 353.975 |
| 10:35 ET | 400 | 353.68 |
| 10:37 ET | 100 | 355 |
| 10:39 ET | 100 | 353.685 |
| 10:42 ET | 500 | 353.62 |
| 10:44 ET | 814 | 353.26 |
| 10:53 ET | 125 | 354.065 |
| 11:00 ET | 100 | 353.915 |
| 11:02 ET | 4669 | 353.915 |
| 11:08 ET | 125 | 353.33 |
| 11:11 ET | 100 | 354.56 |
| 11:13 ET | 100 | 354.56 |
| 11:18 ET | 100 | 354.555 |
| 11:22 ET | 100 | 354.88 |
| 11:24 ET | 100 | 354.96 |
| 11:26 ET | 200 | 354.725 |
| 11:27 ET | 100 | 354.715 |
| 11:31 ET | 2343 | 354.83 |
| 11:42 ET | 100 | 355.005 |
| 11:44 ET | 100 | 355.01 |
| 11:58 ET | 100 | 355.565 |
| 12:00 ET | 761 | 355.37 |
| 12:02 ET | 100 | 355.34 |
| 12:03 ET | 900 | 355.275 |
| 12:05 ET | 200 | 355.21 |
| 12:09 ET | 377 | 355.16 |
| 12:14 ET | 100 | 355.24 |
| 12:16 ET | 400 | 355.34 |
| 12:18 ET | 200 | 355.38 |
| 12:21 ET | 100 | 355.425 |
| 12:23 ET | 100 | 355.765 |
| 12:27 ET | 100 | 355.76 |
| 12:32 ET | 1063 | 355.395 |
| 12:43 ET | 100 | 354.825 |
| 12:48 ET | 312 | 354.19 |
| 12:50 ET | 100 | 353.83 |
| 12:52 ET | 400 | 353.685 |
| 12:54 ET | 200 | 353.565 |
| 12:56 ET | 100 | 353.05 |
| 12:59 ET | 141 | 353.9399 |
| 01:01 ET | 174 | 353.26 |
| 01:03 ET | 119 | 353.445 |
| 01:12 ET | 600 | 352.82 |
| 01:14 ET | 481 | 353.16 |
| 01:21 ET | 200 | 352.855 |
| 01:24 ET | 183 | 352.788 |
| 01:30 ET | 100 | 353.16 |
| 01:33 ET | 100 | 353.1 |
| 01:37 ET | 100 | 353.5 |
| 01:44 ET | 2082 | 352.245 |
| 01:46 ET | 100 | 352.49 |
Sep 24, 2024
United Therapeutics to Feature Clinical Data Across its Commercial and Development Portfolio at the CHEST 2024 Annual Meeting, from 7:00AM ET on Tuesday Sep 24, 2024 by Dow Jones
7:00AM ET on Tuesday Sep 24, 2024 by Dow Jones
Sep 23, 2024
DJ United Therapeutics Is Maintained at Buy by Jefferies, from 11:30AM ET on Monday Sep 23, 2024 by Dow Jones
11:30AM ET on Monday Sep 23, 2024 by Dow Jones
Sep 16, 2024
DJ Liquidia Says U.S. Court Found United Therapeutics Caused Losses of More Than $137M, from 10:34AM ET on Monday Sep 16, 2024 by Dow Jones
10:34AM ET on Monday Sep 16, 2024 by Dow Jones
Sep 10, 2024
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
United Therapeutics Corp | 15.7B | 16.2x | +8.22% |
Biomarin Pharmaceutical Inc | 13.3B | 51.5x | --- |
Exact Sciences Corp | 12.4B | -69.7x | --- |
Neurocrine Biosciences Inc | 11.5B | 33.8x | +62.04% |
Qiagen NV | 9.9B | 136.9x | +12.66% |
Medpace Holdings Inc | 10.4B | 31.8x | +35.10% |
Company Information
United Therapeutics Corporation is a pharmaceutical company. It markets and sells commercial therapies to treat pulmonary arterial hypertension (PAH): Tyvaso DPI (treprostinil) Inhalation Powder (Tyvaso DPI); Tyvaso (treprostinil) Inhalation Solution (nebulized Tyvaso), which includes the Tyvaso Inhalation System; Remodulin (treprostinil) Injection (Remodulin); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca). Tyvaso DPI and nebulized Tyvaso are also approved to treat pulmonary hypertension associated with interstitial lung disease (PH-ILD). It also markets and sells an oncology product, Unituxin (dinutuximab) Injection (Unituxin) for treatment of high-risk neuroblastoma, and the Remunity Pump for Remodulin (Remunity). Tyvaso DPI is a drug-device combination product that incorporates the dry powder formulation technology and Dreamboat inhalation device technology used in MannKind’s Afrezza (insulin human) Inhalation Powder.
Contact Information
- Headquarters
- 1000 SPRING STSILVER SPRING, MD, United States 20910
- Phone
- 301-608-9292
- Fax
- 301-608-9291
Executives
- Chairman of the Board, Chief Executive Officer
- Martine Rothblatt
- President, Chief Operating Officer
- Michael Benkowitz
- Lead Independent Vice Chairman of the Board
- Christopher Patusky
- Chief Financial Officer, Treasurer
- James Edgemond
- Executive Vice President, General Counsel, Corporate Secretary
- Paul Mahon
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $15.7B |
|---|---|
Revenue (TTM) | $2.6B |
Shares Outstanding | 44.5M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.57 |
EPS | $21.75 |
Book Value | $127.23 |
P/E Ratio | 16.2x |
Price/Sales (TTM) | 6.0 |
Price/Cash Flow (TTM) | 13.9x |
Operating Margin | 48.28% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
